Liquidia Corporation received a $50 million payment from Healthcare Royalty (HCRx) after initiating commercial sales of YUTREPIA™, its inhaled therapy for pulmonary hypertension. The funding follows a court ruling denying United Therapeutics' injunction against Liquidia. To date, Liquidia has secured $175 million out of a potential $200 million through its agreement with HCRx. The funds will accelerate YUTREPIA’s launch, support clinical trials, and expand manufacturing. An additional $25 million may be accessed if net sales exceed $100 million by mid-2026. Liquidia believes this funding will help reach profitability without needing more capital.